Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Importantly, many individuals with obesity also exhibit clinically relevant subthreshold eating patterns, such as grazing (repetitive, unstructured consumption of small food quantities) [6], the night eating syndrome [7], and emotional eating [8, 9]
Summary: GLP-1 receptor agonists can be safe for seniors when prescribed with careful patient selection, appropriate dose titration, and regular monitoring of tolerability and comorbidities
Clinical Update 2/10/2025 PEA for Menstrual Pain
Key findings across the STEP trials: Average weight loss of ~15% of body weight roughly 15 kg (33 lbs) for a 100 kg (220 lb) person 87% of patients lost at least 5% of body weight, compared to 31% on placebo Nearly 70% of patients lost at least 10% of body weight About 1 in 3 patients lost 20% or more Weight loss was maintained throughout the treatment period with continued medication use Significant improvements in blood pressure, blood sugar, cholesterol, and inflammatory markers alongside weight loss These results are dramatically better than any prior weight loss medication
Clinical trials would need an IND protocol
US$ 20.12
US$ 25.89
US$ 26.76
US$ 24.98
US$ 21.38
US$ 21.13
US$ 22.25
US$ 26.59
